International Prognostic Score for Asymptomatic Early-stage CLL (IPS-E)
The IPS‑E predicts the likelihood of requiring first treatment in asymptomatic early‑stage CLL using IGHV status, lymphocyte count, and palpable lymphadenopathy 1.
Indicações de Uso
Used in asymptomatic early‑stage CLL (Rai 0–I or Binet A) to estimate risk of needing first treatment based on 3 factors (unmutated IGHV, ALC >15×10⁹/L, palpable nodes). Derived and validated in 4933 patients with clear 5‑year TTFT separation: 8% vs 28% vs 61% for low/intermediate/high risk 1 [Level I evidence]. Guides follow‑up intensity, patient counseling, and selection for early‑intervention clinical trials.
Insights e Precauções
Identifies three adverse factors—unmutated IGHV, ALC >15×10⁹/L, palpable nodes—each adding one point and stratifying patients into groups with markedly different 5‑year treatment risks (8%, 28%, 61%) 1 [Level I evidence].
Use only to estimate time to first treatment in asymptomatic early-stage CLL; it does not guide therapy, omits cytogenetics/TP53 status, and may underestimate risk in biologically high‑risk disease.